EdiGene raises $62M to expand gene editing technologies

By The Science Advisory Board staff writers

April 21, 2021 -- Biotech company EdiGene has raised $62 million in financing to expand its genome editing technologies and to accelerate drug discovery and therapies.

This funding adds to the approximately $67 million the company raised in October 2020. Proceeds will be used to advance the company's pipeline into clinics and to scale up global business operations.

This year, the company's lead candidate, an investigational CRISPR/Cas9 gene editing therapy for patients with transfusion dependent beta-thalassemia, was the first hematopoietic stem cell therapy investigational new drug application approval in China. The company is also preparing to initiate a trial for other drug candidates, including allogeneic chimeric antigen receptor (CAR) T-cell therapy and in vivo therapies based on an RNA base editing technology called leveraging endogenous ADAR for programmable editing of RNA (LEAPER).

The series B plus financing round was led by Loyal Valley Capital.


Copyright © 2021 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here